Imagin Medical, Inc. engages in the research, development, and commercialization in the device and instrumentation medical technology industry. The company is headquartered in Vancouver, British Columbia. The firm is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that delivers bipolar, radio frequency energy through a distinctive coil electrode, or cage. The company enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.
IMEXF stock price ended at $0 on 水曜日, after rising NaN%
On the latest trading day Jan 14, 2026, the stock price of IMEXF rose by NaN%, climbing from $0.00 to $0.00. Throughout the session, the stock experienced a volatility of NaN%, with prices fluctuating between a daily low of $0.00 and a high of $0.00. Alongside this price increase, trading volume also rose by 165 shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.3K shares were traded, amounting to a market value of approximately --.